# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: modern shifted

## What we are working on

- Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legs **S**
- Her glucose has dropped low after late shows, once just before an encore **S**
- The vision in her right eye has blurred, and she worries about reading lyrics and set lists **S**

## Your goals

- No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months. Target: 2026-10-26. Recorded outcome: No level 2 or 3 lows since intake; time below 70 mg/dL under 1%. **S**
- A1c below 7.5% by six months. Target: 2026-10-26. Recorded outcome: A1c 7.1%. **S**
- LDL cholesterol below 55 mg/dL by six months. Target: 2026-10-26. Recorded outcome: LDL 48 mg/dL on atorvastatin 80 mg and ezetimibe. **S**
- Walk at least four blocks without stopping by six months. Target: 2026-10-26. Recorded outcome: Walks about five blocks before calf pain. **S**
- No foot ulcer, and protective footwear on and off stage, through six months. Target: 2026-10-26. Recorded outcome: No ulcer; low-heeled custom stage shoes and protective daily shoes. **S**

## What we agreed to do

- Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change. Guideline: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissue. Guideline: The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%). Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Supervised exercise therapy for claudication: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks at a hospital program, with a structured home walking plan for tour weeks; then walking at least three times a week for life. Guideline: 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Low-dose rivaroxaban 2.5 mg twice daily with aspirin 81 mg to lower the risk of heart attack, stroke, and major limb events, with bleeding precautions and no anti-inflammatory painkillers. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Revascularization plan: no procedure now; endovascular treatment of the right superficial femoral artery to be considered if claudication still limits her life after twelve weeks of supervised exercise and medical therapy; urgent vascular review for rest pain, a wound, or color change; ankle-brachial index and duplex at six months. Guideline: The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly, for cardiovascular benefit and walking distance, with the retina clinic told before the start because a fast fall in glucose can briefly worsen retinopathy; ezetimibe 10 mg added for an LDL of 64 mg/dL. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025) **S**

## Follow-up

- 2026-05-11: New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk **S**
- 2026-05-26: Two-week review: glucose and hypoglycemia safety on the new plan, and vascular surgery consultation **S**
- 2026-06-15: Subsequent annual wellness visit **S**
- 2026-08-10: Three-month review: A1c, lipids, walking program, eye treatment, and foot care **S**
- 2026-10-26: Five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up **S**

This teaching document does not replace care from a qualified clinician.
